Treatment for IgA Vasculitis with Renal Involvement
For IgA vasculitis (IgAV) with renal involvement, initiate supportive care with ACE inhibitors or ARBs and blood pressure control as first-line therapy; add corticosteroids for patients with persistent proteinuria ≥1 g/day despite 3-6 months of optimized supportive care and preserved kidney function (GFR >50 ml/min per 1.73 m²), or immediately for rapidly progressive crescentic disease with cyclophosphamide.
Initial Risk Stratification and Supportive Care
The treatment approach depends critically on the severity of renal involvement at presentation 1:
Mild-to-moderate renal involvement (proteinuria <1 g/day, stable kidney function):
- Start ACE inhibitor or ARB therapy, titrating upward as tolerated
- Target blood pressure <130/80 mmHg if proteinuria <1 g/day
- Target blood pressure <125/75 mmHg if proteinuria >1 g/day 2, 1
- Monitor proteinuria, blood pressure, and kidney function closely for 3-6 months
Persistent significant proteinuria (≥1 g/day after 3-6 months of optimized supportive care):
- Add a 6-month course of corticosteroid therapy if GFR >50 ml/min per 1.73 m² 2, 1
- Common regimens include oral prednisone starting at 0.8-1 mg/kg/day for 2 months, then taper, or pulse IV methylprednisolone (1g for 3 days) followed by oral steroids 2
Severe Renal Involvement
Rapidly progressive crescentic IgAV nephritis (≥50% crescents on biopsy with rapidly deteriorating kidney function):
- Treat analogously to ANCA-associated vasculitis 1
- Use combination of glucocorticoids plus cyclophosphamide 1
- This represents a medical emergency requiring immediate immunosuppression
- Consider plasma exchange for serum creatinine >3.4 mg/dl (>300 μmol/L) or dialysis-dependent patients, though evidence is limited 3
Important Caveats and Clinical Pitfalls
Corticosteroid timing matters: While corticosteroids are frequently used for extrarenal manifestations (purpura, arthritis, abdominal pain), their early administration does not prevent subsequent kidney involvement 4. However, once renal disease develops with significant proteinuria, corticosteroids become indicated to prevent long-term kidney injury 5.
Do not use prophylactic steroids: Systematic reviews demonstrate that steroids do not prevent renal complications when given prophylactically for extrarenal symptoms alone 6. Reserve immunosuppression for documented renal involvement meeting treatment thresholds.
Avoid certain immunosuppressants: Do not use mycophenolate mofetil as primary therapy for IgAV nephritis, as evidence from IgA nephropathy studies suggests it is inferior to other options 1. Similarly, avoid corticosteroids combined with azathioprine unless treating crescentic disease 1.
Monitoring and Follow-up
- Assess proteinuria, blood pressure, and kidney function at diagnosis and during follow-up 1
- Continue monitoring for at least 6 months after apparent remission, as renal involvement can relapse years later 6
- In children, target proteinuria <0.5-1 g/day/1.73 m² with blood pressure below the 90th percentile for age and gender 2
Emerging Considerations
Recent advances in IgA nephropathy treatment (SGLT2 inhibitors, targeted-release budesonide, endothelin receptor antagonists) may have future applicability to IgAV nephritis given the shared pathogenesis, though current evidence is insufficient for routine recommendation 7, 8, 9. Rituximab has shown promise in case series for refractory IgAV but lacks controlled trial data 8, 10.
The key principle is treat-to-target: aim to reduce proteinuria to <1 g/day through stepwise intensification of therapy, as this threshold correlates with favorable long-term kidney outcomes 1.